GSK Jemperli sBLA Priority Review: Rectal Cancer Organ-Preservation Race

The FDA has accepted for Priority Review GSK’s supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in previously untreated stage II and III mismatch repair-deficient (dMMR) / microsatellite instability-high (MSI-H) locally advanced rectal cancer, according to a report from The Pharma Letter dated August 24, 2026. The filing moves one of oncology’s most closely watched treatment paradigms — chemotherapy-free, organ-preserving immunotherapy for rectal cancer — one step closer to a formal FDA label.

The acceptance is the regulatory echo of the finding that made Memorial Sloan Kettering’s checkpoint-inhibitor rectal cancer cohort famous: in the original MSK study of dostarlimab in dMMR stage II/III rectal cancer, every one of the first dozen-plus patients who completed six months of therapy had a complete clinical response, with no need for chemoradiotherapy or surgery at the time of reporting. The results, published in the New England Journal of Medicine and updated repeatedly since, have been described as a potential cure for a subset of rectal cancer patients — and a threat to the standard chemoradiation-plus-surgery pathway that leaves many patients with permanent colostomies, neuropathy, and fertility loss.

Why the label matters

Rectal cancer affects roughly 46,000 people in the U.S. annually, and 5% to 10% of cases are dMMR/MSI-H — between roughly 2,500 and 4,500 patients per year who are eligible for an immunotherapy-first approach. The prize is not patient volume; it is the precedent. An FDA label for organ preservation in a solid tumor would be the first of its kind, and it changes the treatment calculus for every MSI-H gastrointestinal cancer that follows: complete clinical response without resection as a registrational endpoint.

For GSK (GSK), Jemperli is a modest commercial asset today — the drug was approved in 2021 for dMMR recurrent or advanced endometrial cancer and has since picked up an expanded tumor-agnostic indication for MSI-H solid tumors, but sales remain a rounding error against oncology blockbusters, running in the low hundreds of millions annually against company revenue of roughly £31 billion. A rectal cancer label adds a curative-intent, earlier-line population where Jemperli would be the only approved immunotherapy option. That is how immuno-oncology franchises compound: one indication at a time, each moving earlier in the disease.

The competitive backdrop

GSK is not the only company chasing MSI-H rectal cancer. MSD’s Keytruda has the broadest MSI-H tumor-agnostic label in the setting of advanced disease, and checkpoint inhibitors from Bristol Myers Squibb (Opdivo plus Yervoy) and others have produced deep response rates in MSI-H GI cancers. But the neoadjuvant, organ-preservation niche in rectal cancer specifically has been dostarlimab’s signature study — the MSK trial was designed around dostarlimab — and the new sBLA appears to leverage that program and its follow-up data. A granted Priority Review (6-month clock rather than the standard 10) signals the FDA sees a meaningful advance over existing therapy. Watch for the PDUFA date in the acceptance letter disclosure, which we will add to the FDA calendar once GSK confirms it.

The risk in these filings is always the endpoint. Organ preservation claims rest on complete clinical response durability — follow-up must show that patients who skip surgery do not relapse — and GSK will need mature data to convert any accelerated approval into full approval. Our guide to what an sNDA is covers how supplemental labels typically expand; a rectal cancer first-line organ-preservation claim would be among the most significant label expansions in recent memory.

What to watch

Three things move this story from here. First, the PDUFA date itself — likely landing in early-to-mid 2027 given Priority Review timing. Second, whether the FDA convenes an advisory committee, which for a paradigm-shifting endpoint is a real possibility; our AdCom explainer covers why that matters for traders. Third, GSK’s broader oncology buildout: the company has been rebuilding a post-Zejula, post-Zantac pipeline, and Jemperli’s expansion is one of the few commercial proof points. For a company trading near multi-year highs on RSV and vaccine strength, an organ-preservation label is upside optionality the market has not priced.

For biotech investors, the larger lesson is that MSI-H is becoming a franchise-level opportunity across tumor types. The same biomarker that drives Jemperli’s rectal filing drives tumor-agnostic approvals for Keytruda, and next-generation bispecifics and ADCs are queuing up behind them. We cover the mismatch-repair story and related diagnostics in our guide to clinical trial endpoints.

Source: The Pharma Letter, August 24, 2026 | GSK investor relations